8-K: STERIS to Pay $48.15 Million to Settle Ethylene Oxide Claims in Illinois

STERIS plc subsidiary, Isomedix, has reached agreements to settle ethylene oxide-related personal injury claims in Illinois for up to $48.15 million.

Summary

• STERIS plc's subsidiary, Isomedix Operations, Inc., has entered into binding term sheets and settlement agreements to resolve substantially all pending personal injury claims related to ethylene oxide (EO) emissions in Cook County, Illinois.
• The settlement involves payments of up to $48.15 million to the plaintiffs.
• The agreements do not constitute an admission of liability or that the Waukegan, Illinois facility posed a safety hazard.
• Isomedix retains the right to withdraw from the agreements if certain conditions are not met, such as a substantial majority of plaintiffs not agreeing to settle or court disapproval.
• The settlement will be funded through a combination of existing cash reserves and borrowings from the company's revolving credit facility.
• STERIS will record a $48.15 million charge for the settlement in its fiscal year ending March 31, 2025, which will be excluded from adjusted earnings measures.
• The claims administration process is expected to take up to 10 months.
• Isomedix anticipates dismissal of all pending EO-related claims brought by the covered plaintiffs upon completion of the claims administration process and approval by the court.

Sentiment

Score: 6

Explanation: While the settlement resolves a significant legal issue, it comes at a substantial financial cost. The lack of admission of liability is a positive, but the overall impact is neutral to slightly negative.

Positives

• The settlement aims to resolve a significant portion of the pending EO-related claims, potentially reducing future legal uncertainties.
• The company has walkaway rights if certain conditions are not met, providing some protection.
• The settlement allows the company to move forward and focus on its core business.

Negatives

• The settlement will result in a $48.15 million charge to earnings in fiscal year 2025.
• The settlement requires the use of cash on hand and borrowings, potentially impacting financial flexibility.
• The claims administration process is expected to take up to 10 months, creating a period of uncertainty.

Risks

• Isomedix may exercise walkaway rights if certain agreed terms are not fulfilled.
• The claims administration process may face unforeseen delays or complications.
• The settlement is subject to court approval, which is not guaranteed.
• The company faces risks related to public health crises, supply chain disruptions, and changes in market conditions.
• The company faces risks related to tax treatments under the TCJA and the IRA.
• The company faces risks related to international unrest, including the Russia-Ukraine or Israel-Hamas military conflicts.

Future Outlook

The company anticipates dismissal of all pending EO-related claims brought by the covered plaintiffs upon completion of the claims administration process and approval by the court.

Industry Context

The settlement reflects the ongoing scrutiny and legal challenges faced by companies using ethylene oxide, a sterilizing agent, and highlights the potential financial impact of environmental and health-related litigation.

Legal Proceedings

• Isomedix Operations, Inc. (Isomedix), a subsidiary of STERIS plc (STERIS or the Company), entered into binding confidential term sheets with plaintiffs counsel (the Term Sheets), as well as settlement agreements with several plaintiffs currently scheduled for trial.
• The Term Sheets and the settlement agreements are expected to resolve substantially all of the claims for personal injury related to ethylene oxide (EO) that are currently pending in the Circuit Court of Cook County, Illinois.

Stakeholder Impact

• Shareholders will see a one-time charge to earnings.
• The settlement could reduce long-term uncertainty and potential future liabilities.
• The settlement could improve the company's reputation by addressing community concerns.

Next Steps

• Isomedix will deposit the settlement funds into escrow.
• The claims administration process will be established, including guidelines and procedures for administering individual settlements.
• The claims administration process is expected to take up to 10 months to complete.
• Isomedix anticipates dismissal of all pending EO-related claims brought by the covered plaintiffs upon completion of the claims administration process and approval by the court.

Key Dates